Literature DB >> 17971596

Projecting individualized probabilities of developing bladder cancer in white individuals.

Xifeng Wu1, Jie Lin, H Barton Grossman, Maosheng Huang, Jian Gu, Carol J Etzel, Christopher I Amos, Colin P Dinney, Margaret R Spitz.   

Abstract

PURPOSE: There has been no risk assessment model for bladder cancer (BC). We developed the first model incorporating mutagen sensitivity and epidemiologic factors to predict BC risk. PATIENTS AND METHODS: We used epidemiologic and genetic data from a large case-control study to build the models and constructed receiver operating characteristic curves. The area under the curve (AUC) was used to evaluate model discriminatory ability. We also projected absolute risk of developing BC by taking into account competing causes of death.
RESULTS: The study included 678 white BC patients and 678 controls. Significant risk factors in the epidemiologic model included pack-years smoked and exposures to diesel, aromatic amines, dry cleaning fluids, radioactive materials, and arsenic. This model yielded good discriminatory ability (AUC = 0.70; 95% CI, 0.67 to 0.73). When mutagen sensitivity data were incorporated, the AUC increased to 0.80 (95% CI, 0.72 to 0.82). The models showed excellent concordance in the internal validation. We also computed an easy to use ordinal risk score and provided examples for projecting absolute risk.
CONCLUSION: We have developed the first risk prediction model for BC. The enhanced model integrating the genetic factor exhibited excellent discriminatory ability. Our model only requires an individual to answer a few simple questions during a clinic visit to project individualized probability. This model may be used as a basis for developing a Web-based tool for BC risk assessment. Validation of our model in an external population is an essential next step towards practical use in the clinical setting.

Entities:  

Mesh:

Year:  2007        PMID: 17971596     DOI: 10.1200/JCO.2007.10.7557

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  31 in total

Review 1.  Is there a rationale for bladder cancer screening?

Authors:  Robert S Svatek; Yair Lotan
Journal:  Curr Urol Rep       Date:  2008-09       Impact factor: 3.092

2.  Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer.

Authors:  Moubin Lin; Liren Zhang; Michelle A T Hildebrandt; Maosheng Huang; Xifeng Wu; Yuanqing Ye
Journal:  Oncotarget       Date:  2017-08-24

3.  Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk.

Authors:  Jie Lin; Michele R Forman; Jianming Wang; H Barton Grossman; Meng Chen; Colin P Dinney; Ernest T Hawk; Xifeng Wu
Journal:  Int J Cancer       Date:  2012-03-06       Impact factor: 7.396

4.  DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer.

Authors:  Carmen J Marsit; Devin C Koestler; Brock C Christensen; Margaret R Karagas; E Andres Houseman; Karl T Kelsey
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

5.  The more from East-Asian, the better: risk prediction of colorectal cancer risk by GWAS-identified SNPs among Japanese.

Authors:  Makiko Abe; Hidemi Ito; Isao Oze; Masatoshi Nomura; Yoshihiro Ogawa; Keitaro Matsuo
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-28       Impact factor: 4.553

6.  Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer.

Authors:  Montserrat Garcia-Closas; Nathaniel Rothman; Jonine D Figueroa; Ludmila Prokunina-Olsson; Summer S Han; Dalsu Baris; Eric J Jacobs; Nuria Malats; Immaculata De Vivo; Demetrius Albanes; Mark P Purdue; Sapna Sharma; Yi-Ping Fu; Manolis Kogevinas; Zhaoming Wang; Wei Tang; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Margaret R Karagas; Alan Schned; Gerald Andriole; Robert Grubb; Amanda Black; Susan M Gapstur; Michael Thun; William Ryan Diver; Stephanie J Weinstein; Jarmo Virtamo; David J Hunter; Neil Caporaso; Maria Teresa Landi; Amy Hutchinson; Laurie Burdett; Kevin B Jacobs; Meredith Yeager; Joseph F Fraumeni; Stephen J Chanock; Debra T Silverman; Nilanjan Chatterjee
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

Review 7.  Pharmacogenomics of platinum-based chemotherapy in NSCLC.

Authors:  Michelle A T Hildebrandt; Jian Gu; Xifeng Wu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-07       Impact factor: 4.481

8.  Comparison of discriminatory power and accuracy of three lung cancer risk models.

Authors:  A M D'Amelio; A Cassidy; K Asomaning; O Y Raji; S W Duffy; J K Field; M R Spitz; D Christiani; C J Etzel
Journal:  Br J Cancer       Date:  2010-06-29       Impact factor: 7.640

9.  Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer.

Authors:  Mariana C Stern; Jie Lin; Jonine D Figueroa; Karl T Kelsey; Anne E Kiltie; Jian-Min Yuan; Giuseppe Matullo; Tony Fletcher; Simone Benhamou; Jack A Taylor; Donatella Placidi; Zuo-Feng Zhang; Gunnar Steineck; Nathaniel Rothman; Manolis Kogevinas; Debra Silverman; Nuria Malats; Stephen Chanock; Xifeng Wu; Margaret R Karagas; Angeline S Andrew; Heather H Nelson; D Timothy Bishop; Sei Chung Sak; Ananya Choudhury; Jennifer H Barrett; Faye Elliot; Román Corral; Amit D Joshi; Manuela Gago-Dominguez; Victoria K Cortessis; Yong-Bing Xiang; Yu-Tang Gao; Paolo Vineis; Carlotta Sacerdote; Simonetta Guarrera; Silvia Polidoro; Alessandra Allione; Eugen Gurzau; Kvetoslava Koppova; Rajiv Kumar; Peter Rudnai; Stefano Porru; Angela Carta; Marcello Campagna; Cecilia Arici; Sung Shim Lani Park; Montserrat Garcia-Closas
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

10.  Risk of urinary bladder cancer: a case-control analysis of industry and occupation.

Authors:  Adrian Cassidy; Wei Wang; Xifeng Wu; Jie Lin
Journal:  BMC Cancer       Date:  2009-12-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.